Memphasys Limited (ASX:MEM)

Market Cap	7.93M
Revenue (ttm)	1.07M
Net Income (ttm)	-5.11M
Shares Out	1.98B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,500
Average Volume	1,446,367
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0030 - 0.0110
Beta	0.41
RSI	44.97
Earnings Date	Aug 29, 2025

About Intra-Cellular Therapies

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 24
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MEM

Financial Performance

In 2024, Memphasys's revenue was 1.09 million, an increase of 74.55% compared to the previous year's 624,370. Losses were -4.44 million, 30.5% more than in 2023.